REARDON ANDREW (CLO & Secretary) sold 11.9% of their position (5K shares) of LIGAND PHARMACEUTICALS INC on the open market
Open‑market sale worth $1.03M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
+5K
Price / share
$52.27
Trade value
$261.35K
% of position
Common Stock
Shares
−100.00
Price / share
$197.70
Trade value
$19.77K
% of position
Common Stock
Shares
−100.00
Price / share
$199.00
Trade value
$19.90K
% of position
Common Stock
Shares
−207.00
Price / share
$199.96
Trade value
$41.39K
% of position
Common Stock
Shares
−93.00
Price / share
$200.62
Trade value
$18.66K
% of position
Common Stock
Shares
−300.00
Price / share
$201.70
Trade value
$60.51K
% of position
Common Stock
Shares
−200.00
Price / share
$204.17
Trade value
$40.83K
% of position
Common Stock
Shares
−460.00
Price / share
$205.18
Trade value
$94.38K
% of position
Common Stock
Shares
−340.00
Price / share
$206.37
Trade value
$70.16K
% of position
Common Stock
Shares
−612.00
Price / share
$207.01
Trade value
$126.69K
% of position
Common Stock
Shares
−1.45K
Price / share
$208.12
Trade value
$300.94K
% of position
Common Stock
Shares
−1.14K
Price / share
$208.87
Trade value
$238.53K
% of position
Net shares
+0.00
Net value
-$770.42K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/4/2026 | M · Option Exercise | +5K | $52.27 | $261.35K | 13.6% | 36.87K | 41.87K |
| Common Stock Direct | 3/4/2026 | S · Sale | −100.00 | $197.70 | $19.77K | 0.2% | 41.87K | 41.77K |
| Common Stock Direct | 3/4/2026 | S · Sale | −100.00 | $199.00 | $19.90K | 0.2% | 41.77K | 41.67K |
| Common Stock Direct | 3/4/2026 | S · Sale | −207.00 | $199.96 | $41.39K | 0.5% | 41.67K | 41.46K |
| Common Stock Direct | 3/4/2026 | S · Sale | −93.00 | $200.62 | $18.66K | 0.2% | 41.46K | 41.37K |
| Common Stock Direct | 3/4/2026 | S · Sale | −300.00 | $201.70 | $60.51K | 0.7% | 41.37K | 41.07K |
| Common Stock Direct | 3/4/2026 | S · Sale | −200.00 | $204.17 | $40.83K | 0.5% | 41.07K | 40.87K |
| Common Stock Direct | 3/4/2026 | S · Sale | −460.00 | $205.18 | $94.38K | 1.1% | 40.87K | 40.41K |
| Common Stock Direct | 3/4/2026 | S · Sale | −340.00 | $206.37 | $70.16K | 0.8% | 40.41K | 40.07K |
| Common Stock Direct | 3/4/2026 | S · Sale | −612.00 | $207.01 | $126.69K | 1.5% | 40.07K | 39.46K |
| Common Stock Direct | 3/4/2026 | S · Sale | −1.45K | $208.12 | $300.94K | 3.7% | 39.46K | 38.01K |
| Common Stock Direct | 3/4/2026 | S · Sale | −1.14K | $208.87 | $238.53K | 3.0% | 38.01K | 36.87K |
| Total | +0.00 | -$770.42K | ||||||
Employee Stock Option (right to buy)
Common Stock
5K shares
Shares
−5K
Strike price
52.27
Held after
54.44K
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock5K shares | 3/4/2026 | M · Option Exercise | −5K | 52.27 | — | 54.44K |